NEW YORK, April 8, 2024 /PRNewswire/ -- Lucid Diagnostics
Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a
commercial-stage, cancer prevention medical diagnostics company,
and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ)
( "PAVmed"), today announced that Lucid's President & Chief
Operating Officer Shaun O'Neil will
participate in a fireside chat at the 23rd Annual Needham Virtual
Healthcare Conference on Thursday, April 11,
2024, at 11:00 a.m. E.T.
The fireside chat will be webcast live and can be accessed by
visiting the Investor Relations Section of the Lucid Diagnostics
website or by clicking here. A replay of the webcast will be
available on the website for 30 days following the conclusion of
the live broadcast. Company management will meet with investors in
one-on-one meetings during the conference.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a
commercial-stage medical diagnostics company focused on cancer
prevention, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is
focused on the millions of patients with gastroesophageal reflux
disease (GERD), also known as chronic heartburn, who are at risk of
developing esophageal precancer and cancer. Lucid's
EsoGuard® Esophageal DNA Test, performed on samples
collected in a brief, noninvasive office procedure with its
EsoCheck Esophageal Cell Collection Device, is the first and only
commercially available diagnostic test capable of serving as a
widespread screening tool for at-risk patients to mitigate the
risks of cancer and cancer deaths through early detection of
esophageal precancer.
For more information, please visit www.luciddx.com and
for more information about its parent company PAVmed, please
visit www.pavmed.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-participate-in-fireside-chat-at-the-23rd-annual-needham-virtual-healthcare-conference-302110087.html
SOURCE Lucid Diagnostics